-
1
-
-
67349277390
-
Local communication on and within bone controls bone remodeling
-
Henriksen K, Neutzsky-Wulff AV, Bonewald LF et al. Local communication on and within bone controls bone remodeling. Bone 44, 1026-1033 (2009).
-
(2009)
Bone
, vol.44
, pp. 1026-1033
-
-
Henriksen, K.1
Neutzsky-Wulff, A.V.2
Bonewald, L.F.3
-
2
-
-
33646889773
-
Bone quality - The material and structural basis of bone strength and fragility
-
Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250-2261 (2006).
-
(2006)
N. Engl. J. Med
, vol.354
, pp. 2250-2261
-
-
Seeman, E.1
Delmas, P.D.2
-
3
-
-
79951655957
-
Osteoclast activity and subtypes as a function of physiology and pathology - Implications for future treatments of osteoporosis
-
Henriksen K, Bollerslev J, Everts V et al. Osteoclast activity and subtypes as a function of physiology and pathology - implications for future treatments of osteoporosis. Endocr. Rev. 32, 31-63 (2011).
-
(2011)
Endocr. Rev.
, vol.32
, pp. 31-63
-
-
Henriksen, K.1
Bollerslev, J.2
Everts, V.3
-
4
-
-
34547463285
-
Epidemiology of osteoporotic fractures
-
Favus MJ (Ed.). American Society for Bone and Mineral Research, Washington, DC, USA
-
Harvey N, Earl S, Cooper C. Epidemiology of osteoporotic fractures. In:Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (6th Edition). Favus MJ (Ed.). American Society for Bone and Mineral Research, Washington, DC, USA, 244-248 (2006).
-
(2006)
Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (6th Edition)
, pp. 244-248
-
-
Harvey, N.1
Earl, S.2
Cooper, C.3
-
5
-
-
33846332080
-
New mechanisms and targets in the treatment of bone fragility
-
DOI 10.1042/CS20060046
-
Martin TJ, Seeman E. New mechanisms and targets in the treatment of bone fragility. Clin. Sci. [Lond.] 112, 77-91 (2007). (Pubitemid 46120088)
-
(2007)
Clinical Science
, vol.112
, Issue.1-2
, pp. 77-91
-
-
Martin, T.J.1
Seeman, E.2
-
6
-
-
38949204304
-
Pathogenesis of postmenopausal osteoporosis
-
Favus MJ (Ed.). American Society for Bone and Mineral Research, Washington, DC, USA
-
Eastell R. Pathogenesis of postmenopausal osteoporosis. In:Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (6th Edition). Favus MJ (Ed.). American Society for Bone and Mineral Research, Washington, DC, USA, 259-262 (2006).
-
(2006)
Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (6th Edition)
, pp. 259-262
-
-
Eastell, R.1
-
7
-
-
42649130844
-
Assessing fracture risk: Who should be screened
-
Favus MJ (Ed.). American Society for Bone and Mineral Research, Washington, DC, USA
-
Schousboe JT, Taylor BC, Ensrud KE. Assessing fracture risk: who should be screened. In:Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (6th Edition). Favus MJ (Ed.). American Society for Bone and Mineral Research, Washington, DC, USA, 262-267 (2006).
-
(2006)
Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (6th Edition)
, pp. 262-267
-
-
Schousboe, J.T.1
Taylor, B.C.2
Ensrud, K.E.3
-
8
-
-
79960621438
-
The WHO absolute fracture risk models [FRAX®]: Do clinical risk factors improve fracture prediction in older women without osteoporosis?
-
Hillier TA, Cauley JA, Rizzo JH et al. The WHO absolute fracture risk models [FRAX®]: do clinical risk factors improve fracture prediction in older women without osteoporosis? J. Bone Miner. Res. 26, 1774-1782 (2011).
-
(2011)
J. Bone Miner. Res.
, vol.26
, pp. 1774-1782
-
-
Hillier, T.A.1
Cauley, J.A.2
Rizzo, J.H.3
-
9
-
-
79960915428
-
Official positions for FRAX clinical regarding biochemical markers from joint official positions development conference of the international society for clinical densitometry and international osteoporosis foundation on FRAX
-
McCloskey EV, Vasikaran S, Cooper C. Official positions for FRAX clinical regarding biochemical markers from joint official positions development conference of the international society for clinical densitometry and international osteoporosis foundation on FRAX. J. Clin. Densitom. 14, 220-222 (2011).
-
(2011)
J. Clin. Densitom.
, vol.14
, pp. 220-222
-
-
McCloskey, E.V.1
Vasikaran, S.2
Cooper, C.3
-
10
-
-
66149103673
-
Biochemical markers and the FDA critical path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development
-
Karsdal MA, Henriksen K, Leeming DJ et al. Biochemical markers and the FDA critical path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14, 181-202 (2009).
-
(2009)
Biomarkers
, vol.14
, pp. 181-202
-
-
Ma, K.1
Henriksen, K.2
Leeming, D.J.3
-
11
-
-
0027525577
-
Long-term fracture prediction by bone mineral assessed at different skeletal sites
-
Melton LJ 3rd, Atkinson EJ, OFallon WM et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J. Bone Miner. Res. 8, 1227-1233 (1993). (Pubitemid 23308116)
-
(1993)
Journal of Bone and Mineral Research
, vol.8
, Issue.10
, pp. 1227-1233
-
-
Melton III, L.J.1
Atkinson, E.J.2
O'Fallon, W.M.3
Wahner, H.W.4
Riggs, B.L.5
-
12
-
-
0346344235
-
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
-
DOI 10.1056/NEJM199802193380801
-
Hosking D, Chilvers CE, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group. N. Engl. J. Med. 338, 485-492 (1998). (Pubitemid 28103131)
-
(1998)
New England Journal of Medicine
, vol.338
, Issue.8
, pp. 485-492
-
-
Hosking, D.1
Chilvers, C.E.D.2
Christiansen, C.3
Ravn, P.4
Wasnich, R.5
Ross, P.6
Mcclung, M.7
Balske, A.8
Thompson, D.9
Daley, M.10
Yates, A.J.11
-
13
-
-
0030893199
-
Hormone replacement therapy in the prevention and treatment of osteoporosis
-
Delmas PD. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporos. Int. 7(Suppl. 1), S3-S7 (1997
-
(1997)
Osteoporos. Int.
, vol.7
, Issue.SUPPL. 1
-
-
Delmas, P.D.1
-
14
-
-
0024594671
-
Nasal calcitonin for treatment of established osteoporosis
-
Overgaard K, Riis BJ, Christiansen C et al. Nasal calcitonin for treatment of established osteoporosis. Clin. Endocrinol. (Oxf.) 30, 435-442 (1989). (Pubitemid 19110017)
-
(1989)
Clinical Endocrinology
, vol.30
, Issue.4
, pp. 435-442
-
-
Overgaard, K.1
Riis, B.J.2
Christiansen, C.3
Podenphant, J.4
Johansen, J.S.5
-
15
-
-
78651493109
-
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards
-
Vasikaran S, Eastell R, Bruyere O et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 22, 391-420 (2011).
-
(2011)
Osteoporos. Int.
, vol.22
, pp. 391-420
-
-
Vasikaran, S.1
Eastell, R.2
Bruyere, O.3
-
16
-
-
33749499825
-
An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice
-
DOI 10.1007/s00228-006-0174-3
-
Leeming DJ, Alexandersen P, Karsdal MA et al. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur. J. Clin. Pharmacol. 62, 781-792 (2006). (Pubitemid 44521426)
-
(2006)
European Journal of Clinical Pharmacology
, vol.62
, Issue.10
, pp. 781-792
-
-
Leeming, D.J.1
Alexandersen, P.2
Karsdal, M.A.3
Qvist, P.4
Schaller, S.5
Tanko, L.B.6
-
17
-
-
0034141218
-
Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: A biological clock of protein aging with clinical potential
-
DOI 10.1042/0264-6021:3450473
-
Cloos PA, Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem. J. 345(Pt 3), 473-480 (2000). (Pubitemid 30099075)
-
(2000)
Biochemical Journal
, vol.345
, Issue.3
, pp. 473-480
-
-
Cloos, P.A.C.1
Fledelius, C.2
-
18
-
-
1642422776
-
Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline
-
DOI 10.1007/s00774-003-0460-4
-
Okabe R, Inaba M, Nakatsuka K et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J. Bone Miner. Metab. 22, 127-131 (2004). (Pubitemid 38405041)
-
(2004)
Journal of Bone and Mineral Metabolism
, vol.22
, Issue.2
, pp. 127-131
-
-
Okabe, R.1
Inaba, M.2
Nakatsuka, K.3
Miki, T.4
Naka, H.5
Moriguchi, A.6
Nishizawa, Y.7
-
19
-
-
0033932263
-
The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women
-
Chaki O, Yoshikata I, Kikuchi R et al. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J. Bone Miner. Res. 15, 1537-1544 (2000). (Pubitemid 30484523)
-
(2000)
Journal of Bone and Mineral Research
, vol.15
, Issue.8
, pp. 1537-1544
-
-
Chaki, O.1
Yoshikata, I.2
Kikuchi, R.3
Nakayama, M.4
Uchiyama, Y.5
Hirahara, F.6
Gorai, I.7
-
20
-
-
1842739009
-
Possibilities of monitoring bone metabolism in ruminants - An overview of the methods in use
-
Liesegang A. Possibilities of monitoring bone metabolism in ruminants: an overview of the methods in use. Acta Vet. Scand. Suppl. 97, 23-28 (2003). (Pubitemid 38469650)
-
(2003)
Acta Veterinaria Scandinavica, Supplement
, Issue.97
, pp. 23-28
-
-
Liesegang, A.1
-
21
-
-
33645457788
-
The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients
-
Leeming DJ, Koizumi M, Byrjalsen I et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 15, 32-38 (2006).
-
(2006)
Cancer Epidemiol. Biomarkers Prev.
, vol.15
, pp. 32-38
-
-
Leeming, D.J.1
Koizumi, M.2
Byrjalsen, I.3
-
22
-
-
34047185276
-
Assessment of osteoclast number and function: Application in the development of new and improved treatment modalities for bone diseases
-
DOI 10.1007/s00198-006-0286-8
-
Henriksen K, Tanko LB, Qvist P et al. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos. Int. 18, 681-685 (2007). (Pubitemid 46525540)
-
(2007)
Osteoporosis International
, vol.18
, Issue.5
, pp. 681-685
-
-
Henriksen, K.1
Tanko, L.B.2
Qvist, P.3
Delmas, P.D.4
Christiansen, C.5
Karsdal, M.A.6
-
23
-
-
70350591051
-
Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate
-
Munoz-Torres M, Reyes-Garcia R, Mezquita-Raya P et al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Maturitas 64, 188-192 (2009).
-
(2009)
Maturitas
, vol.64
, pp. 188-192
-
-
Munoz-Torres, M.1
Reyes-Garcia, R.2
Mezquita-Raya, P.3
-
24
-
-
79960397931
-
Procollagen type i N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats
-
Veidal SS, Vassiliadis E, Bay-Jensen AC et al. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 3, 5 (2010).
-
Fibrogenesis Tissue Repair
, vol.3
, Issue.5
, pp. 2010
-
-
Veidal, S.S.1
Vassiliadis, E.2
Bay-Jensen, A.C.3
-
25
-
-
84856639090
-
Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients
-
DOI: 10.1093/ndt/ gfr270 Epub ahead of print
-
Cejka D, Jager-Lansky A, Kieweg H et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol. Dial. Transplant DOI: 10.1093/ndt/ gfr270 (2011) (Epub ahead of print).
-
(2011)
Nephrol. Dial. Transplant
-
-
Cejka, D.1
Jager-Lansky, A.2
Kieweg, H.3
-
26
-
-
80155124726
-
Acute decline in serum sclerostin in response to PTH infusion in healthy men
-
DOI: 10.1210/jc.2011-1534 Epub ahead of print
-
Yu EW, Kumbhani R, Siwila-Sackman E et al. Acute decline in serum sclerostin in response to PTH infusion in healthy men. J. Clin. Endocrinol. Metab. DOI: 10.1210/jc.2011- 1534 (2011) (Epub ahead of print).
-
(2011)
J. Clin. Endocrinol. Metab.
-
-
Yu, E.W.1
Kumbhani, R.2
Siwila-Sackman, E.3
-
27
-
-
77957846460
-
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men
-
Modder UI, Hoey KA, Amin S et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J. Bone Miner. Res. 26, 373-379 (2011).
-
(2011)
J. Bone Miner. Res.
, vol.26
, pp. 373-379
-
-
Modder, U.I.1
Hoey, K.A.2
Amin, S.3
-
28
-
-
79251589954
-
The role of Dkk1 in bone mass regulation: Correlating serum Dkk1 expression with bone mineral density
-
Butler JS, Murray DW, Hurson CJ et al. The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J. Orthop. Res. 29, 414-418 (2011).
-
(2011)
J. Orthop. Res.
, vol.29
, pp. 414-418
-
-
Butler, J.S.1
Murray, D.W.2
Hurson, C.J.3
-
29
-
-
10144251796
-
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
-
Garnero P, Hausherr E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J. Bone Miner. Res. 11, 1531-1538 (1996). (Pubitemid 26331009)
-
(1996)
Journal of Bone and Mineral Research
, vol.11
, Issue.10
, pp. 1531-1538
-
-
Garnero, P.1
Hausherr, E.2
Chapuy, M.-C.3
Marcelli, C.4
Grandjean, H.5
Muller, C.6
Cormier, C.7
Breart, G.8
Meunier, P.J.9
Delmas, P.D.10
-
30
-
-
0034526238
-
Prediction of bone loss in postmenopausal women
-
DOI 10.1007/s001980070005
-
Stepan JJ. Prediction of bone loss in postmenopausal women. Osteoporos. Int. 11(Suppl. 6), S45-S54 (2000). (Pubitemid 32039512)
-
(2000)
Osteoporosis International
, vol.11
, Issue.SUPPL. 6
-
-
Stepan, J.J.1
-
31
-
-
0034526072
-
The use of biochemical markers of bone turnover in osteoporosis. Committee of scientific advisors of the international osteoporosis foundation
-
Delmas PD, Eastell R, Garnero P et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of scientific advisors of the international osteoporosis foundation. Osteoporos. Int. 11(Suppl. 6), S2-S17 (2000).
-
(2000)
Osteoporos. Int.
, vol.11
, Issue.SUPPL. 6
-
-
Delmas, P.D.1
Eastell, R.2
Garnero, P.3
-
32
-
-
34249751708
-
Are nonresorbing osteoclasts sources of bone anabolic activity?
-
DOI 10.1359/jbmr.070109
-
Karsdal MA, Martin TJ, Bollerslev J et al. Are nonresorbing osteoclasts sources of bone anabolic activity? J. Bone Miner. Res. 22, 487-494 (2007). (Pubitemid 47457424)
-
(2007)
Journal of Bone and Mineral Research
, vol.22
, Issue.4
, pp. 487-494
-
-
Karsdal, M.A.1
Martin, T.J.2
Bollerslev, J.3
Christiansen, C.4
Henriksen, K.5
-
33
-
-
0032796234
-
Biochemical markers of bone turnover and prediction of hip bone loss in older women: The study of osteoporotic fractures
-
DOI 10.1359/jbmr.1999.14.8.1404
-
Bauer DC, Sklarin PM, Stone KL et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J. Bone Miner. Res. 14, 1404-1410 (1999). (Pubitemid 29368303)
-
(1999)
Journal of Bone and Mineral Research
, vol.14
, Issue.8
, pp. 1404-1410
-
-
Bauer, D.C.1
Sklarin, P.M.2
Stone, K.L.3
Black, D.M.4
Nevitt, M.C.5
Ensrud, K.E.6
Arnaud, C.D.7
Genant, H.K.8
Garnero, P.9
Delmas, P.D.10
Lawaetz, H.11
Cummings, S.R.12
-
34
-
-
0030969030
-
Relationship of bone turnover to bone density and fractures
-
DOI 10.1359/jbmr.1997.12.7.1083
-
Melton LJ, III, Khosla S, Atkinson EJ et al. Relationship of bone turnover to bone density and fractures. J. Bone Miner. Res. 12, 1083-1091 (1997). (Pubitemid 27264222)
-
(1997)
Journal of Bone and Mineral Research
, vol.12
, Issue.7
, pp. 1083-1091
-
-
Melton III, L.J.1
Khosla, S.2
Atkinson, E.J.3
O'Fallon, W.M.4
Riggs, B.L.5
-
35
-
-
1642367713
-
Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study
-
DOI 10.1016/j.bone.2003.12.021, PII S8756328203004794
-
Bagger YZ, Tanko LB, Alexandersen P et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34, 728-735 (2004). (Pubitemid 38393810)
-
(2004)
Bone
, vol.34
, Issue.4
, pp. 728-735
-
-
Bagger, Y.Z.1
Tanko, L.B.2
Alexandersen, P.3
Hansen, H.B.4
Mollgaard, A.5
Ravn, P.6
Qvist, P.7
Kanis, J.A.8
Christiansen, C.9
-
36
-
-
0036894672
-
Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: Evidence from the national osteoporosis risk assessment
-
Miller PD, Siris ES, Barrett-Connor E et al. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J. Bone Miner. Res. 17, 2222-2230 (2002). (Pubitemid 35416756)
-
(2002)
Journal of Bone and Mineral Research
, vol.17
, Issue.12
, pp. 2222-2230
-
-
Miller, P.D.1
Siris, E.S.2
Barrett-Connor, E.3
Faulkner, K.G.4
Wehren, L.E.5
Abbott, T.A.6
Chen, Y.-T.7
Berger, M.L.8
Santora, A.C.9
Sherwood, L.M.10
-
37
-
-
0942268144
-
Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study
-
DOI 10.1016/j.bone.2003.10.001
-
Schuit SC, van der KM, Weel AE et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34, 195-202 (2004). (Pubitemid 38142449)
-
(2004)
Bone
, vol.34
, Issue.1
, pp. 195-202
-
-
Schuit, S.C.E.1
Van Der Klift, M.2
Weel, A.E.A.M.3
De Laet, C.E.D.H.4
Burger, H.5
Seeman, E.6
Hofman, A.7
Uitterlinden, A.G.8
Van Leeuwen, J.P.T.M.9
Pols, H.A.P.10
-
38
-
-
0343517092
-
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study
-
Garnero P, Sornay-Rendu E, Claustrat B et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J. Bone Miner. Res. 15, 1526-1536 (2000). (Pubitemid 30484522)
-
(2000)
Journal of Bone and Mineral Research
, vol.15
, Issue.8
, pp. 1526-1536
-
-
Patrick, G.1
Sornay-Rendu, E.2
Claustrat, B.3
Delmas, P.D.4
-
39
-
-
25444438208
-
Identification of osteopenic women at high risk of fracture: The OFELY study
-
DOI 10.1359/JBMR.050609
-
Sornay-Rendu E, Munoz F, Garnero P et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J. Bone Miner. Res. 20, 1813-1819 (2005). (Pubitemid 41361882)
-
(2005)
Journal of Bone and Mineral Research
, vol.20
, Issue.10
, pp. 1813-1819
-
-
Sornay-Rendu, E.1
Munoz, F.2
Garnero, P.3
Duboeuf, F.4
Delmas, P.D.5
-
40
-
-
0031698795
-
Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study
-
DOI 10.1007/s001980050100
-
Garnero P, Dargent-Molina P, Hans D et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos. Int. 8, 563-569 (1998). (Pubitemid 28566972)
-
(1998)
Osteoporosis International
, vol.8
, Issue.6
, pp. 563-569
-
-
Garnero, P.1
Dargent-Molina, P.2
Hans, D.3
Schott, A.M.4
Breart, G.5
Meunier, P.J.6
Delmas, P.D.7
-
41
-
-
0037466335
-
Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women
-
DOI 10.1016/S0378-5122(03)00042-2
-
Bruyere O, Collette J, Delmas P et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 44, 259-265 (2003). (Pubitemid 36412177)
-
(2003)
Maturitas
, vol.44
, Issue.4
, pp. 259-265
-
-
Bruyere, O.1
Collette, J.2
Delmas, P.3
Rouillon, A.4
Roux, C.5
Seidel, L.6
Richy, F.7
Reginster, J.-Y.8
-
42
-
-
2942730031
-
Biochemical markers of bone metabolism and prediction of fracture in elderly women
-
DOI 10.1359/JBMR.0301244
-
Gerdhem P, Ivaska KK, Alatalo SL et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J. Bone Miner. Res. 19, 386-393 (2004). (Pubitemid 38787393)
-
(2004)
Journal of Bone and Mineral Research
, vol.19
, Issue.3
, pp. 386-393
-
-
Gerdhem, P.1
Ivaska, K.K.2
Alatalo, S.L.3
Halleen, J.M.4
Hellman, J.5
Isaksson, A.6
Pettersson, K.7
Vaananen, H.K.8
Akesson, K.9
Obrant, K.J.10
-
43
-
-
33744733717
-
Mechanisms involved in skeletal anabolic therapies
-
DOI 10.1196/annals.1346.043
-
Martin TJ, Quinn JM, Gillespie MT et al. Mechanisms involved in skeletal anabolic therapies. Ann. NY Acad. Sci. 1068, 458-470 (2006). (Pubitemid 43824174)
-
(2006)
Annals of the New York Academy of Sciences
, vol.1068
, Issue.1
, pp. 458-470
-
-
Martin, T.J.1
Quinn, J.M.W.2
Gillespie, M.T.3
Ng, K.W.4
Karsdal, M.A.5
Sims, N.A.6
-
44
-
-
78049522060
-
Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect
-
Eisman JA, Bone HG, Hosking DJ et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26, 242-251 (2010).
-
(2010)
J. Bone Miner. Res.
, vol.26
, pp. 242-251
-
-
Eisman, J.A.1
Bone, H.G.2
Hosking, D.J.3
-
45
-
-
79951615188
-
Lessons learned from the development of oral calcitonin: The first tablet formulation of a peptide in Phase III clinical trials
-
Karsdal MA, Henriksen K, Bay-Jensen AC et al. Lessons learned from the development of oral calcitonin: the first tablet formulation of a peptide in Phase III clinical trials. J. Clin. Pharmacol. 51, 460-471 (2010).
-
(2010)
J. Clin. Pharmacol.
, vol.51
, pp. 460-471
-
-
Ma, K.1
Henriksen, K.2
Bay-Jensen, A.C.3
-
46
-
-
78650958526
-
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
-
Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19-26 (2011).
-
(2011)
J. Bone Miner. Res.
, vol.26
, pp. 19-26
-
-
Padhi, D.1
Jang, G.2
Stouch, B.3
Fang, L.4
Posvar, E.5
-
47
-
-
33846840695
-
Disassociation of bone resorption and formation by GLP-2. A 14-day study in healthy postmenopausal women
-
DOI 10.1016/j.bone.2006.09.025, PII S8756328206007459
-
Henriksen DB, Alexandersen P, Hartmann B et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 40, 723-729 (2007). (Pubitemid 46201945)
-
(2007)
Bone
, vol.40
, Issue.3
, pp. 723-729
-
-
Henriksen, D.B.1
Alexandersen, P.2
Hartmann, B.3
Adrian, C.L.4
Byrjalsen, I.5
Bone, H.G.6
Holst, J.J.7
Christiansen, C.8
-
48
-
-
77953433829
-
Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase i trial
-
Hannon RA, Clack G, Rimmer M et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase I trial. J. Bone Miner. Res. 25, 463-471 (2010
-
(2010)
J. Bone Miner. Res.
, vol.25
, pp. 463-471
-
-
Hannon, R.A.1
Clack, G.2
Rimmer, M.3
-
49
-
-
19944432718
-
Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption
-
Karsdal MA, Henriksen K, Sorensen MG et al. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am. J. Pathol. 166, 467-476 (2005). (Pubitemid 40189043)
-
(2005)
American Journal of Pathology
, vol.166
, Issue.2
, pp. 467-476
-
-
Karsdal, M.A.1
Henriksen, K.2
Sorensen, M.G.3
Gram, J.4
Schaller, S.5
Dziegiel, M.H.6
Heegaard, A.-M.7
Christophersen, P.8
Martin, T.J.9
Christiansen, C.10
Bollerslev, J.11
-
50
-
-
12344279757
-
The chloride channel inhibitor N53736 prevents bone resorption in ovariectomized rats without changing bone formation
-
DOI 10.1359/JBMR.040302
-
Schaller S, Henriksen K, Sveigaard C et al. The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J. Bone Miner. Res. 19, 1144-1153 (2004). (Pubitemid 41110567)
-
(2004)
Journal of Bone and Mineral Research
, vol.19
, Issue.7
, pp. 1144-1153
-
-
Schaller, S.1
Henriksen, K.2
Sveigaard, C.3
Heegaard, A.-M.4
Helix, N.5
Stahlhut, M.6
Ovejero, M.C.7
Johansen, J.V.8
Solberg, H.9
Andersen, T.L.10
Hougaard, D.11
Berryman, M.12
Shiodt, C.B.13
Sorensen, B.H.14
Lichtenberg, J.15
Christophersen, P.16
Foged, N.T.17
Delaisse, J.-M.18
Engsig, M.T.19
Karsdal, M.A.20
more..
-
51
-
-
0033829969
-
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
-
PROOF study group
-
Chesnut CH 3rd, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group. Am. J. Med. 109, 267-276 (2000).
-
(2000)
Am. J. Med.
, vol.109
, pp. 267-276
-
-
Chesnut III, C.H.1
Silverman, S.2
Andriano, K.3
-
52
-
-
16644391022
-
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: Acute and 3-month effects on biomarkers of bone turnover
-
DOI 10.1359/JBMR.040715
-
Tanko LB, Bagger YZ, Alexandersen P et al. Safety and efficacy of a novel salmon calcitonin [sCT] technology-based oral formulation in healthy postmenopausal women: acute and 3 month effects on biomarkers of bone turnover. J. Bone Miner. Res. 19, 1531-1538 (2004). (Pubitemid 41094356)
-
(2004)
Journal of Bone and Mineral Research
, vol.19
, Issue.9
, pp. 1531-1538
-
-
Tanko, L.B.1
Bagger, Y.Z.2
Alexandersen, P.3
Devogelaer, J.-P.4
Reginster, J.-Y.5
Chick, R.6
Olson, M.7
Benmammar, H.8
Mindeholm, L.9
Azria, M.10
Christiansen, C.11
-
53
-
-
0942300651
-
Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption
-
DOI 10.1016/j.bone.2003.04.002
-
Hannon RA, Clowes JA, Eagleton AC et al. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34, 187-194 (2004). (Pubitemid 38142448)
-
(2004)
Bone
, vol.34
, Issue.1
, pp. 187-194
-
-
Hannon, R.A.1
Clowes, J.A.2
Eagleton, A.C.3
Al Hadari, A.4
Eastell, R.5
Blumsohn, A.6
-
54
-
-
14644407147
-
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study
-
DOI 10.1359/jbmr.2005.20.1.141
-
Rosen CJ, Hochberg MC, Bonnick SL et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20, 141-151 (2005). (Pubitemid 41716229)
-
(2005)
Journal of Bone and Mineral Research
, vol.20
, Issue.1
, pp. 141-151
-
-
Rosen, C.J.1
Hochberg, M.C.2
Bonnick, S.L.3
McClung, M.4
Miller, P.5
Broy, S.6
Kagan, R.7
Chen, E.8
Petruschke, R.A.9
Thompson, D.E.10
De Papp, A.E.11
-
55
-
-
65549105437
-
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study
-
Emkey R, Delmas PD, Bolognese M et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clin. Ther. 31, 751-761 (2009).
-
(2009)
Clin. Ther.
, vol.31
, pp. 751-761
-
-
Emkey, R.1
Delmas, P.D.2
Bolognese, M.3
-
56
-
-
20844432225
-
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
-
DOI 10.1359/JBMR.050309
-
Arlot M, Meunier PJ, Boivin G et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J. Bone Miner. Res. 20, 1244-1253 (2005). (Pubitemid 40863814)
-
(2005)
Journal of Bone and Mineral Research
, vol.20
, Issue.7
, pp. 1244-1253
-
-
Arlot, M.1
Meunier, P.J.2
Boivin, G.3
Haddock, L.4
Tamayo, J.5
Correa-Rotter, R.6
Jasqui, S.7
Donley, D.W.8
Dalsky, G.P.9
San Martin, J.10
Eriksen, E.F.11
-
57
-
-
33745034449
-
Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study
-
DOI 10.1002/art.21918
-
Delmas PD, Adami S, Strugala C et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 54, 1838-1846 (2006). (Pubitemid 43877933)
-
(2006)
Arthritis and Rheumatism
, vol.54
, Issue.6
, pp. 1838-1846
-
-
Delmas, P.D.1
Adami, S.2
Strugala, C.3
Stakkestad, J.A.4
Reginster, J.-Y.5
Felsenberg, D.6
Christiansen, C.7
Civitelli, R.8
Drezner, M.K.9
Recker, R.R.10
Bolognese, M.11
Hughes, C.12
Masanauskaite, D.13
Ward, P.14
Sambrook, P.15
Reid, D.M.16
-
58
-
-
4344580653
-
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study
-
DOI 10.1007/s00198-004-1602-9
-
Delmas PD, Recker RR, Chesnut CH 3rd et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos. Int. 15, 792-798 (2004). (Pubitemid 39361949)
-
(2004)
Osteoporosis International
, vol.15
, Issue.10
, pp. 792-798
-
-
Delmas, P.D.1
Recker, R.R.2
Chesnut III, C.H.3
Skag, A.4
Stakkestad, J.A.5
Emkey, R.6
Gilbride, J.7
Schimmer, R.C.8
Christiansen, C.9
-
59
-
-
34247866550
-
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
-
DOI 10.1056/NEJMoa067312
-
Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809-1822 (2007). (Pubitemid 46698462)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.18
, pp. 1809-1822
-
-
Black, D.M.1
Delmas, P.D.2
Eastell, R.3
Reid, I.R.4
Boonen, S.5
Cauley, J.A.6
Cosman, F.7
Lakatos, P.8
Ping, C.L.9
Man, Z.10
Mautalen, C.11
Mesenbrink, P.12
Hu, H.13
Caminis, J.14
Tong, K.15
Rosario-Jansen, T.16
Krasnow, J.17
Hue, T.F.18
Sellmeyer, D.19
Eriksen, E.F.20
Cummings, S.R.21
more..
-
60
-
-
69049083492
-
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
-
Cummings SR, San MJ, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009).
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 756-765
-
-
Cummings, S.R.1
San, M.J.2
McClung, M.R.3
-
61
-
-
45149124792
-
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women
-
DOI 10.1210/jc.2007-2814
-
Bone HG, Bolognese MA, Yuen CK et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93, 2149-2157 (2008). (Pubitemid 351831529)
-
(2008)
Journal of Clinical Endocrinology and Metabolism
, vol.93
, Issue.6
, pp. 2149-2157
-
-
Bone, H.G.1
Bolognese, M.A.2
Yuen, C.K.3
Kendler, D.L.4
Wang, H.5
Liu, Y.6
San Martin, J.7
-
62
-
-
79951746928
-
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
-
Eastell R, Christiansen C, Grauer A et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 530-537 (2010).
-
(2010)
J. Bone Miner. Res.
, vol.26
, pp. 530-537
-
-
Eastell, R.1
Christiansen, C.2
Grauer, A.3
-
63
-
-
0036635349
-
The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women
-
DOI 10.1111/j.1471-0528.2002.01177.x, PII S1470032802011771
-
Pereda CA, Hannon RA, Naylor KE et al. The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women. BJOG 109, 812-820 (2002). (Pubitemid 37329258)
-
(2002)
BJOG: An International Journal of Obstetrics and Gynaecology
, vol.109
, Issue.7
, pp. 812-820
-
-
Pereda, C.A.1
Hannon, R.A.2
Naylor, K.E.3
Eastell, R.4
-
64
-
-
77649187377
-
The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women
-
Naylor KE, Clowes JA, Finigan J et al. The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. Bone 46, 592-597 (2010).
-
(2010)
Bone
, vol.46
, pp. 592-597
-
-
Naylor, K.E.1
Clowes, J.A.2
Finigan, J.3
-
65
-
-
6544261973
-
Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene
-
DOI 10.1007/s001980050236
-
Meunier PJ, Vignot E, Garnero P et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene study group. Osteoporos. Int. 10, 330-336 (1999). (Pubitemid 29476199)
-
(1999)
Osteoporosis International
, vol.10
, Issue.4
, pp. 330-336
-
-
Meunier, P.J.1
Vignot, E.2
Garnero, P.3
Confavreux, E.4
Paris, E.5
Liu-Leage, S.6
Sarkar, S.7
Liu, T.8
Wong, M.9
Draper, M.W.10
-
66
-
-
0033581212
-
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
-
DOI 10.1001/jama.282.7.637
-
Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282, 637-645 (1999). (Pubitemid 29384151)
-
(1999)
Journal of the American Medical Association
, vol.282
, Issue.7
, pp. 637-645
-
-
Ettinger, B.1
Black, D.M.2
Mitlak, B.H.3
Knickerbocker, R.K.4
Nickelsen, T.5
Genant, H.K.6
Christiansen, C.7
Delmas, P.D.8
Zanchetta, J.R.9
Stakkestad, J.10
Gluer, C.C.11
Krueger, K.12
Cohen, F.J.13
Eckert, S.14
Ensrud, K.E.15
Avioli, L.V.16
Lips, P.17
Cummings, S.R.18
-
67
-
-
18344379873
-
Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis - A 2-year randomized placebo controlled trial
-
DOI 10.1210/jc.87.5.2060
-
Meunier PJ, Slosman DO, Delmas PD et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2 year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 87, 2060-2066 (2002). (Pubitemid 34521489)
-
(2002)
Journal of Clinical Endocrinology and Metabolism
, vol.87
, Issue.5
, pp. 2060-2066
-
-
Meunier, P.J.1
Slosman, D.O.2
Delmas, P.D.3
Sebert, J.L.4
Brandi, M.L.5
Albanese, C.6
Lorenc, R.7
Pors-Nielsen, S.8
De Vernejoul, M.C.9
Roces, A.10
Reginster, J.Y.11
-
68
-
-
80052337245
-
The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: Results of a randomized, open-label clinical trial
-
Quesada-Gomez JM, Muschitz C, Gomez-Reino J et al. The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial. Osteoporos. Int. 22, 2529-2537 (2010).
-
(2010)
Osteoporos. Int.
, vol.22
, pp. 2529-2537
-
-
Quesada-Gomez, J.M.1
Muschitz, C.2
Gomez-Reino, J.3
-
69
-
-
77953510486
-
Odanacatib, a cathepsin K inhibitor for osteoporosis: A 2 year study in postmenopausal women with low bone density
-
Bone HG, McClung MR, Roux C et al. Odanacatib, a cathepsin K inhibitor for osteoporosis: a 2 year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25, 937-947 (2009).
-
(2009)
J. Bone Miner. Res.
, vol.25
, pp. 937-947
-
-
Bone, H.G.1
McClung, M.R.2
Roux, C.3
-
70
-
-
79958803353
-
Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study
-
Eastell R, Nagase S, Ohyama M et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study. J. Bone Miner. Res. 26, 1303-1312 (2011).
-
(2011)
J. Bone Miner. Res.
, vol.26
, pp. 1303-1312
-
-
Eastell, R.1
Nagase, S.2
Ohyama, M.3
-
71
-
-
70349279885
-
Four-month treatment with GLP-2 significantly increases hip BMD: A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
-
Henriksen DB, Alexandersen P, Hartmann B et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 45, 833-842 (2009).
-
(2009)
Bone
, vol.45
, pp. 833-842
-
-
Henriksen, D.B.1
Alexandersen, P.2
Hartmann, B.3
-
72
-
-
70350230386
-
Rapid and robust response of biochemical markers of bone formation to teriparatide therapy
-
Glover SJ, Eastell R, McCloskey EV et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45, 1053-1058 (2009).
-
(2009)
Bone
, vol.45
, pp. 1053-1058
-
-
Glover, S.J.1
Eastell, R.2
McCloskey, E.V.3
-
73
-
-
23444452077
-
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
-
DOI 10.1056/NEJMoa050336
-
Black DM, Bilezikian JP, Ensrud KE et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med. 353, 555-565 (2005). (Pubitemid 41138937)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.6
, pp. 555-565
-
-
Black, D.M.1
Bilezikian, J.P.2
Ensrud, K.E.3
Greenspan, S.L.4
Palermo, L.5
Hue, T.6
Lang, T.F.7
McGowan, J.A.8
Rosen, C.J.9
-
74
-
-
45149119618
-
Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling
-
DOI 10.1210/jc.2007-2781
-
Black DM, Bouxsein ML, Palermo L et al. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J. Clin. Endocrinol. Metab. 93, 2166-2172 (2008). (Pubitemid 351831531)
-
(2008)
Journal of Clinical Endocrinology and Metabolism
, vol.93
, Issue.6
, pp. 2166-2172
-
-
Black, D.M.1
Bouxsein, M.L.2
Palermo, L.3
McGowan, J.A.4
Newitt, D.C.5
Rosen, E.6
Majumdar, S.7
Rosen, C.J.8
-
75
-
-
0034519794
-
Preanalytical variability of biochemical markers of bone turnover
-
DOI 10.1007/s001980070004
-
Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos. Int. 11(Suppl. 6), S30-S44 (2000). (Pubitemid 32039511)
-
(2000)
Osteoporosis International
, vol.11
, Issue.SUPPL. 6
-
-
Hannon, R.1
Eastell, R.2
-
76
-
-
0043125769
-
Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis
-
DOI 10.1016/S8756-3282(03)00168-6
-
Ravn P, Thompson DE, Ross PD et al. Biochemical markers for prediction of 4 year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33, 150-158 (2003). (Pubitemid 36957958)
-
(2003)
Bone
, vol.33
, Issue.1
, pp. 150-158
-
-
Ravn, P.1
Thompson, D.E.2
Ross, P.D.3
Christiansen, C.4
-
77
-
-
0141625900
-
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
-
DOI 10.1359/jbmr.2003.18.6.1051
-
Eastell R, Barton I, Hannon RA et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 18, 1051-1056 (2003). (Pubitemid 37294942)
-
(2003)
Journal of Bone and Mineral Research
, vol.18
, Issue.6
, pp. 1051-1056
-
-
Eastell, R.1
Barton, I.2
Hannon, R.A.3
Chines, A.4
Garnero, P.5
Delmas, P.D.6
-
78
-
-
2942739433
-
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk
-
DOI 10.1359/JBMR.0301243
-
Sarkar S, Reginster JY, Crans GG et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J. Bone Miner. Res. 19, 394-401 (2004). (Pubitemid 38787394)
-
(2004)
Journal of Bone and Mineral Research
, vol.19
, Issue.3
, pp. 394-401
-
-
Sarkar, S.1
Reginster, J.-Y.2
Crans, G.G.3
Diez-Perez, A.4
Pinette, K.V.5
Delmas, P.D.6
-
79
-
-
0035664686
-
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis
-
DOI 10.1007/s001980170020
-
Bjarnason NH, Sarkar S, Duong T et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos. Int. 12, 922-930 (2001). (Pubitemid 34001005)
-
(2001)
Osteoporosis International
, vol.12
, Issue.11
, pp. 922-930
-
-
Bjarnason, N.H.1
Sarkar, S.2
Duong, T.3
Mitlak, B.4
Delmas, P.D.5
Christiansen, C.6
-
80
-
-
19044364417
-
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis
-
DOI 10.1359/JBMR.050105
-
Chen P, Satterwhite JH, Licata AA et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20, 962-970 (2005). (Pubitemid 40712820)
-
(2005)
Journal of Bone and Mineral Research
, vol.20
, Issue.6
, pp. 962-970
-
-
Chen, P.1
Satterwhite, J.H.2
Licata, A.A.3
Lewiecki, E.M.4
Sipos, A.A.5
Misurski, D.M.6
Wagman, R.B.7
-
81
-
-
77954565409
-
Relationship between 3 month changes in biochemical markers of bone remodeling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years
-
Bruyere O, Collette J, Rizzoli R et al. Relationship between 3 month changes in biochemical markers of bone remodeling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos. Int. 21, 1031-1036 (2009).
-
(2009)
Osteoporos. Int.
, vol.21
, pp. 1031-1036
-
-
Bruyere, O.1
Collette, J.2
Rizzoli, R.3
-
83
-
-
77953433829
-
Effects of the src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase i trial
-
Hannon RA, Clack G, Rimmer M et al. Effects of the src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase I trial. J. Bone Miner. Res. 25, 463-471 (2010).
-
(2010)
J. Bone Miner. Res.
, vol.25
, pp. 463-471
-
-
Hannon, R.A.1
Clack, G.2
Rimmer, M.3
-
84
-
-
0036309083
-
Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting
-
DOI 10.1016/S8756-3282(02)00791-3, PII S8756328202007913
-
Qvist P, Christgau S, Pedersen BJ et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31, 57-61 (2002). (Pubitemid 34754426)
-
(2002)
Bone
, vol.31
, Issue.1
, pp. 57-61
-
-
Qvist, P.1
Christgau, S.2
Pedersen, B.J.3
Schlemmer, A.4
Christiansen, C.5
-
85
-
-
52949084000
-
Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of salmon calcitonin
-
Karsdal MA, Byrjalsen I, Riis BJ et al. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin. BMC Clin. Pharmacol. 8, 5 (2008).
-
(2008)
BMC Clin. Pharmacol.
, vol.8
, pp. 5
-
-
Ma, K.1
Byrjalsen, I.2
Riis, B.J.3
-
86
-
-
58149327054
-
Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin
-
Karsdal MA, Byrjalsen I, Riis BJ et al. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin. Pharmacol. 8, 12 (2008).
-
(2008)
BMC Clin. Pharmacol.
, vol.8
, pp. 12
-
-
Ma, K.1
Byrjalsen, I.2
Riis, B.J.3
-
87
-
-
58849158708
-
A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin
-
Karsdal MA, Byrjalsen I, Henriksen K et al. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin. J. Clin. Pharmacol. 49, 229-234 (2009).
-
(2009)
J. Clin. Pharmacol.
, vol.49
, pp. 229-234
-
-
Ma, K.1
Byrjalsen, I.2
Henriksen, K.3
-
88
-
-
63849211819
-
Influence of food intake on the bioavailability and efficacy of oral calcitonin
-
Karsdal MA, Byrjalsen I, Azria M et al. Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br. J. Clin. Pharmacol. 67, 413-420 (2009).
-
(2009)
Br. J. Clin. Pharmacol.
, vol.67
, pp. 413-420
-
-
Ma, K.1
Byrjalsen, I.2
Azria, M.3
-
89
-
-
74149092299
-
The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: A 14 day randomized study
-
Karsdal MA, Byrjalsen I, Henriksen K et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14 day randomized study. Osteoarthritis Cartilage 18, 150-159 (2009).
-
(2009)
Osteoarthritis Cartilage
, vol.18
, pp. 150-159
-
-
Ma, K.1
Byrjalsen, I.2
Henriksen, K.3
-
90
-
-
76949084136
-
Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy
-
Karsdal MA, Byrjalsen I, Henriksen K et al. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur. J. Clin. Pharmacol. 66, 29-37 (2009).
-
(2009)
Eur. J. Clin. Pharmacol.
, vol.66
, pp. 29-37
-
-
Ma, K.1
Byrjalsen, I.2
Henriksen, K.3
-
91
-
-
0036233579
-
Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: The OFELY prospective study
-
Garnero P, Cloos P, Sornay-Rendu E et al. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J. Bone Miner. Res. 17, 826-833 (2002). (Pubitemid 34441899)
-
(2002)
Journal of Bone and Mineral Research
, vol.17
, Issue.5
, pp. 826-833
-
-
Garnero, P.1
Cloos, P.2
Sornay-Rendu, E.3
Qvist, P.4
Delmas, P.D.5
-
92
-
-
0030999235
-
Characterization of urinary degradation products derived from type I collagen. Identification of a β-isomerized ASP-GLY sequence within the C- terminal telopeptide (α1) region
-
DOI 10.1074/jbc.272.15.9755
-
Fledelius C, Johnsen AH, Cloos PA et al. Characterization of urinary degradation products derived from type I collagen. Identification of a b-isomerized Asp-Gly sequence within the C-terminal telopeptide (a1) region. J. Biol. Chem. 272, 9755-9763 (1997). (Pubitemid 27171639)
-
(1997)
Journal of Biological Chemistry
, vol.272
, Issue.15
, pp. 9755-9763
-
-
Fledelius, C.1
Johnsen, A.H.2
Cloos, P.A.C.3
Bonde, M.4
Qvist, P.5
-
93
-
-
34247574198
-
Osteoclasts prefer aged bone
-
DOI 10.1007/s00198-006-0298-4
-
Henriksen K, Leeming DJ, Byrjalsen I et al. Osteoclasts prefer aged bone. Osteoporos. Int. 18, 751-759 (2007). (Pubitemid 46684778)
-
(2007)
Osteoporosis International
, vol.18
, Issue.6
, pp. 751-759
-
-
Henriksen, K.1
Leeming, D.J.2
Byrjalsen, I.3
Nielsen, R.H.4
Sorensen, M.G.5
Dziegiel, M.H.6
Martin, T.J.7
Christiansen, C.8
Qvist, P.9
Karsdal, M.A.10
-
94
-
-
38849202528
-
Bone turnover and bone collagen maturation in osteoporosis: Effects of antiresorptive therapies
-
DOI 10.1007/s00198-007-0462-5
-
Byrjalsen I, Leeming DJ, Qvist P et al. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos. Int. 19, 339-348 (2008). (Pubitemid 351199183)
-
(2008)
Osteoporosis International
, vol.19
, Issue.3
, pp. 339-348
-
-
Byrjalsen, I.1
Leeming, D.J.2
Qvist, P.3
Christiansen, C.4
Karsdal, M.A.5
-
95
-
-
49549092964
-
The effects of oral calcitonin on bone collagen maturation: Implications for bone turnover and quality
-
Karsdal MA, Byrjalsen I, Leeming DJ et al. The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos. Int. 19, 1355-1361 (2008).
-
(2008)
Osteoporos. Int.
, vol.19
, pp. 1355-1361
-
-
Ma, K.1
Byrjalsen, I.2
Leeming, D.J.3
-
96
-
-
77953706518
-
Novel combinations of Post-Translational Modification [PTM] neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease?
-
Karsdal MA, Henriksen K, Leeming DJ et al. Novel combinations of Post-Translational Modification [PTM] neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? Clin. Biochem. 43, 793-804 (2010).
-
(2010)
Clin. Biochem.
, vol.43
, pp. 793-804
-
-
Ma, K.1
Henriksen, K.2
Leeming, D.J.3
-
97
-
-
0026675759
-
Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM
-
Sell DR, Lapolla A, Odetti P et al. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41, 1286-1292 (1992).
-
(1992)
Diabetes
, vol.41
, pp. 1286-1292
-
-
Sell, D.R.1
Lapolla, A.2
Odetti, P.3
-
98
-
-
33644698951
-
Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes
-
DOI 10.2337/diabetes.54.11.3103
-
Genuth S, Sun W, Cleary P et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10 year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with Type 1 diabetes. Diabetes 54, 3103-3111 (2005). (Pubitemid 43334362)
-
(2005)
Diabetes
, vol.54
, Issue.11
, pp. 3103-3111
-
-
Genuth, S.1
Sun, W.2
Cleary, P.3
Sell, D.R.4
Dahms, W.5
Malone, J.6
Sivitz, W.7
Monnier, V.M.8
-
99
-
-
23744467295
-
Glycation products as markers and predictors of the progression of diabetic complications
-
DOI 10.1196/annals.1333.065
-
Monnier VM, Sell DR, Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann. NY Acad. Sci. 1043, 567-581 (2005). (Pubitemid 41123947)
-
(2005)
Annals of the New York Academy of Sciences
, vol.1043
, pp. 567-581
-
-
Monnier, V.M.1
Sell, D.R.2
Genuth, S.3
-
100
-
-
76549123888
-
Collagen cross-links as a determinant of bone quality: A possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus
-
Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos. Int. 21, 195-214 (2009).
-
(2009)
Osteoporos. Int.
, vol.21
, pp. 195-214
-
-
Saito, M.1
Marumo, K.2
-
102
-
-
33644503512
-
Collagen glycation and its role in fracture properties of bone
-
Vashishth D. Collagen glycation and its role in fracture properties of bone. J. Musculoskelet. Neuronal Interact. 5, 316 (2005).
-
(2005)
J. Musculoskelet. Neuronal Interact.
, vol.5
, pp. 316
-
-
Vashishth, D.1
-
103
-
-
0141997270
-
E- carboxymethyllysine are elevated in serum of patients with osteoporosis
-
DOI 10.1093/rheumatology/keg324
-
Hein G, Wiegand R, Lehmann G et al. Advanced glycation end-products pentosidine and N e-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxf.) 42, 1242-1246 (2003). (Pubitemid 37258489)
-
(2003)
Rheumatology
, vol.42
, Issue.10
, pp. 1242-1246
-
-
Hein, G.1
Wiegand, R.2
Lehmann, G.3
Stein, G.4
Franke, S.5
-
104
-
-
37349091942
-
Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures
-
DOI 10.1007/s00774-007-0784-6
-
Shiraki M, Kuroda T, Tanaka S et al. Nonenzymatic collagen cross-links induced by glycoxidation [pentosidine] predicts vertebral fractures. J. Bone Miner. Metab. 26, 93-100 (2008). (Pubitemid 350307997)
-
(2008)
Journal of Bone and Mineral Metabolism
, vol.26
, Issue.1
, pp. 93-100
-
-
Shiraki, M.1
Kuroda, T.2
Tanaka, S.3
Saito, M.4
Fukunaga, M.5
Nakamura, T.6
-
105
-
-
76549104637
-
Urinary levels of pentosidine and the risk of fracture in postmenopausal women: The OFELY study
-
Gineyts E, Munoz F, Bertholon C et al. Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study. Osteoporos. Int. 21, 243-250 (2010).
-
(2010)
Osteoporos. Int.
, vol.21
, pp. 243-250
-
-
Gineyts, E.1
Munoz, F.2
Bertholon, C.3
-
106
-
-
25444449013
-
Serum TRACP 5b is a useful marker for monitoring alendronate treatment: Comparison with other markers of bone turnover
-
DOI 10.1359/JBMR.050403
-
Nenonen A, Cheng S, Ivaska KK et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J. Bone Miner. Res. 20, 1804-1812 (2005). (Pubitemid 41361881)
-
(2005)
Journal of Bone and Mineral Research
, vol.20
, Issue.10
, pp. 1804-1812
-
-
Nenonen, A.1
Cheng, S.2
Ivaska, K.K.3
Alatalo, S.L.4
Lehtimaki, T.5
Schmidt-Gayk, H.6
Uusi-Rasi, K.7
Heinonen, A.8
Kannus, P.9
Sievanen, H.10
Vuori, I.11
Vaananen, H.K.12
Halleen, J.M.13
-
107
-
-
2142810972
-
Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schönberg disease (type II autosomal dominant osteopetrosis)
-
DOI 10.1373/clinchem.2003.029355
-
Alatalo SL, Ivaska KK, Waguespack SG et al. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type I autosomal dominant osteopetrosis). Clin. Chem. 50, 883-890 (2004). (Pubitemid 38543667)
-
(2004)
Clinical Chemistry
, vol.50
, Issue.5
, pp. 883-890
-
-
Alatalo, S.L.1
Ivaska, K.K.2
Waguespack, S.G.3
Econs, M.J.4
Vaananen, H.K.5
Halleen, J.M.6
-
108
-
-
32644460848
-
Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease
-
Meier C, Meinhardt U, Greenfield JR et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Pagets disease. Clin. Lab. 52, 1-10 (2006). (Pubitemid 43245859)
-
(2006)
Clinical Laboratory
, vol.52
, Issue.1-2
, pp. 1-10
-
-
Meier, C.1
Meinhardt, U.2
Greenfield, J.R.3
De Winter, J.4
Nguyen, T.V.5
Dunstan, C.R.6
Seibel, M.J.7
|